evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

96 questions · 102 findings · 12 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 24 · 23.5%GRADE not reported 2 · 2%Very low 26 · 25.5%Low 30 · 29.4%Moderate 12 · 11.8%High 8 · 7.8%

Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy

Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea

Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).

1 finding from 1 review

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Change in ocular surface staining at 1‐month (with actual · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).

1 finding from 1 review

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Omega‐3 vs placebo

Diarrhoea · adults and children with cystic fibrosis

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).

1 finding from 1 review

Omega‐3 vs placebo

FEV1 % predicted · adults and children with cystic fibrosis

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FEV1 % predicted compared with placebo (very low certainty).

1 finding from 1 review

Omega‐3 vs placebo

FVC · adults and children with cystic fibrosis

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FVC % predicted compared with placebo (very low certainty).

1 finding from 1 review